Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109).

Dominik Paul Modest,Dominik Noerenberg,Max Seidensticker,Jens Ricke,Uwe M. Martens,Jorge Riera-Knorrenschild,Jobst Greeve,Axel Florschütz,Swen Wessendorf,Thomas Jens Ettrich,Stephan Kanzler,Swantje Held,Petra Buechner-Steudel,Jens Atzpodien,Volker Heinemann,Andrea Tannapfel,Anke Reinacher-Schick,Michael Geissler

Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109).

2019

Dominik Paul Modest
Dominik Noerenberg
Max Seidensticker
Jens Ricke
Uwe M. Martens
Jorge Riera-Knorrenschild
Jobst Greeve
Axel Florschütz
Swen Wessendorf
Thomas Jens Ettrich
Stephan Kanzler
Swantje Held
Petra Buechner-Steudel
Jens Atzpodien
Volker Heinemann
Andrea Tannapfel
Anke Reinacher-Schick
Michael Geissler

3530Background: The VOLFI trial demonstrated improved objective response rate (ORR) with the addition of pmab to modified triplet chemotherapy with FOLFOXIRI in a 2:1 (63 patients FOLFOXIRI plus pm...

Keywords:

FOLFOXIRI
Oxaliplatin
Fluorouracil
Phases of clinical research
Colorectal cancer
Panitumumab
Pathology
Oncology
Folinic acid
Irinotecan
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations